Ameriprise Financial Inc. Has $767,000 Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Ameriprise Financial Inc. increased its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 82.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 89,772 shares of the biopharmaceutical company's stock after buying an additional 40,700 shares during the quarter. Ameriprise Financial Inc. owned 0.06% of Ocular Therapeutix worth $767,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Aptus Capital Advisors LLC lifted its position in shares of Ocular Therapeutix by 29.3% during the 4th quarter. Aptus Capital Advisors LLC now owns 339,750 shares of the biopharmaceutical company's stock worth $2,901,000 after buying an additional 76,940 shares during the period. Freestone Grove Partners LP bought a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $119,000. Northern Trust Corp lifted its position in shares of Ocular Therapeutix by 5.5% during the 4th quarter. Northern Trust Corp now owns 1,314,871 shares of the biopharmaceutical company's stock worth $11,229,000 after buying an additional 68,174 shares during the period. Voya Investment Management LLC raised its position in Ocular Therapeutix by 35.7% in the 4th quarter. Voya Investment Management LLC now owns 371,235 shares of the biopharmaceutical company's stock valued at $3,170,000 after purchasing an additional 97,602 shares during the last quarter. Finally, Hsbc Holdings PLC raised its position in Ocular Therapeutix by 47.8% in the 4th quarter. Hsbc Holdings PLC now owns 18,101 shares of the biopharmaceutical company's stock valued at $152,000 after purchasing an additional 5,853 shares during the last quarter. Institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Trading Up 6.6%

Shares of NASDAQ OCUL traded up $0.56 during midday trading on Friday, hitting $9.02. The stock had a trading volume of 2,152,270 shares, compared to its average volume of 1,408,330. The company's 50-day simple moving average is $7.48 and its 200 day simple moving average is $7.90. The firm has a market cap of $1.44 billion, a P/E ratio of -6.83 and a beta of 1.51. Ocular Therapeutix, Inc. has a fifty-two week low of $4.79 and a fifty-two week high of $11.78. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The firm had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. Research analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Insider Activity

In related news, Director Richard L. Md Lindstrom acquired 10,000 shares of the firm's stock in a transaction that occurred on Thursday, May 8th. The stock was acquired at an average cost of $6.96 per share, with a total value of $69,600.00. Following the completion of the purchase, the director now directly owns 172,704 shares in the company, valued at approximately $1,202,019.84. This trade represents a 6.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Pravin Dugel sold 21,219 shares of Ocular Therapeutix stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $7.18, for a total value of $152,352.42. Following the sale, the insider now directly owns 3,499,099 shares of the company's stock, valued at approximately $25,123,530.82. This trade represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,079 shares of company stock valued at $208,739. Company insiders own 2.30% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Royal Bank of Canada assumed coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research report on Thursday, May 29th. William Blair assumed coverage on Ocular Therapeutix in a research report on Tuesday, April 8th. They issued an "outperform" rating for the company. Needham & Company LLC cut their price objective on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Finally, JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $16.25.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.